Debunking Resistance: A New Approach to ER-Positive Breast Cancer Treatment

Strategic Insights -

Low-dose estrogen therapy, paired with fulvestrant, is being proposed as a promising strategy to maintain tumor control in breast cancer patients whose tumors have become resistant to traditional hormone therapies. Scientists in the United States have discovered that exhaustive antihormonal therapy can lead to two phases of resistance, with estrogen playing a paradoxical role in promoting tumor growth in some cases and inducing apoptosis in others. These findings suggest a new approach to treating patients with ER-positive breast cancer that have failed traditional hormone therapies.

Key Takeaways:

  • Scientists have identified two phases of resistance to selective estrogen receptor modulators (SERMs) and estrogen withdrawal, with estrogen promoting tumor growth in Phase I and inducing apoptosis in Phase II.
  • Paradoxical interactions between fulvestrant and postmenopausal estrogen levels can cause robust growth of Phase II tamoxifen-resistant or aromatase-resistant tumors.
  • The study suggests that low-dose estrogen therapy, followed by fulvestrant in a low estrogen environment, may be a rational approach for maintaining tumor control in patients with ER-positive breast cancer.
  • The findings have clinical relevance, with implications for the development of new treatment strategies for patients with ER-positive breast cancer.
  • Professors V.C. Jordan and colleagues propose using low-dose estrogen therapy to debulk patients followed by fulvestrant in a low estrogen environment to maintain tumor control.

Statistics:

  • 14 million (approximate) cases of breast cancer worldwide each year (Source: World Health Organization)
  • 80% of breast cancers are ER-positive (Source: American Cancer Society)
  • 50% of patients with ER-positive breast cancer will develop resistance to hormone therapies (Source: National Cancer Institute)
  • 2 phases of resistance identified in the study: Phase I (estrogen promotes tumor growth) and Phase II (estrogen induces apoptosis)

Sources:

  • Jordan, V.C., et al. "The Apoptotic Action of Estrogen Following Exhaustive Antihormonal Therapy: A New Clinical Treatment Strategy." Breast, vol. 14, no. 6, 2005, pp. 624-630.
  • World Health Organization. Global Cancer Observatory.
  • American Cancer Society. Breast Cancer Facts & Statistics.
  • National Cancer Institute. Breast Cancer Treatment (PDQ).